



DOCKET NO. 9511-013-27

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kevin J. TRACEY, et al.

ART UNIT: 1626

SERIAL NO.: 09/118,388

EXAMINER: R. Gerstl

FILING DATE: July 17, 1998

FOR: COMPOUNDS AND COMPOSITIONS FOR TREATING TISSUE
ISCHEMIA

RECEIVED
APR 13 2001
TECH CENTER 200/2900
19/6
4/11/01

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the outstanding final Office Action issued on March 2, 2000, and to the subsequent Advisory Action of September 20, 2000, both in the above referenced parent application, Serial No. 09/118,388, the time for response thereto being extended by virtue of the filing of a Notice of Appeal on September 5, 2000 (for which the receipt was date stamped by Patent Office on September 11, 2000), and by petition and extension fees submitted herewith, reconsideration and allowance of the claims pending in this CPA is respectfully requested.

IN THE SPECIFICATION:

Please amend the specification as follows.

Delete last paragraph at page 5, lines 34-36 through page 6, lines 1-3, and insert therefor the following:

--Preferred compounds of formula 1 include, for example, 1-phenacyl-2,3-dicarboxypyridinium bromide; 1-phenacyl-2,4-dicarboxypyridinium bromide; 1-phenacyl-2,5-dicarboxypyridinium bromide; 1-phenacyl-3,5-dicarboxypyridinium bromide (AP5); 1-phenacyl-

Cyber
D1

C